SAB has entered into a definitive merger agreement with Big Cypress Acquisition Corp. (NASDAQ: BCYP) Click to Read More

Click for Webcast Replay

Immunotherapies will never be the same.

The Premise Behind SAb

Ready for rapid response. Because we can.

The speed and sophistication of our platform means we can address global health threats in ways only we can. We’re ready to respond quickly to epidemic-level pathogens, and we’re already developing treatments for some of the world’s most imminent health threats.

  • Media left icon

    Awarded multimillion-dollar contract from the U.S. Department of Defense to develop and test an accelerated and effective rapid response capability, at scale

  • Media right icon

    Recognized as the only therapeutic platform to address priority pathogens by the World Health Organization

Advanced engineering and a refined suite of technologies optimized over nearly two decades